Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory follicular lymphoma with an EZH2 mutation on an FDA-approved test after at least two systemic therapies, or adults with relapsed or refractory disease with no satisfactory alternatives.
LAMPGEN ANALYSIS
Why it matters
Expanded EZH2 inhibition to follicular lymphoma under two historical eligibility routes.
What research teams should watch
Track the biomarker and prior-treatment criteria independently from the no-alternative route.
PRIMARY RECORDS